Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Therapeutics' Sugardown, a dietary supplement was found to reduce post-meal elevation of blood glucose in the clinical trial performed at the University of Sydney.
Subscribe to our email newsletter
Sugardown, a non-systemic dietary supplement, is a complex carbohydrate-based chewable tablet, used to moderate post-meal blood glucose.
The randomized crossover design study of Sugardown was tested at two doses in 10 healthy, non-smoking subjects and showed consumption of Sugardown tablets prior to a high carbohydrate meal in a dose-dependent manner resulted in a 32% reduction in postprandial glucose and a 24% decrease in the postprandial insulin response.
Sugardown is a proprietary polysaccharide designed to be taken before meals and works by suppressing the action of carbohydrate-hydrolyzing enzymes in the gastrointestinal system.
The study also demonstrated that Sugardown tablets, when used as a functional dietary supplement, can have a significant impact in reducing postprandial glucose and insulin responses.
Boston Therapeutics chairman and CEO David Platt said this study, which was co-sponsored by Hong Kong-based Advance Pharmaceutical supports that Sugardown can be a safe dietary supplement for those who struggle with blood sugar management.